alexa The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective.
Pharmaceutical Sciences

Pharmaceutical Sciences

Pharmacoeconomics: Open Access

Author(s): Campbell JD, Spackman DE, Sullivan SD

Abstract Share this page

Abstract BACKGROUND: Omalizumab, an anti-immunoglobulin E antibody, reduces exacerbations and symptoms in uncontrolled allergic asthma. The study objective was to estimate the costs and consequences of omalizumab compared to usual care from a US payer perspective. METHODS: We estimated payer costs, quality-adjusted survival (QALYs), and the incremental cost-effectiveness ratio (ICER) of omalizumab compared to usual care using a state-transition simulation model that included sensitivity analyses. Every 2 weeks, patients could transition between chronic asthma and exacerbation health states. The best available evidence informed the clinical and cost input estimates. Five years of omalizumab treatment followed by usual care was assumed to estimate a lifetime horizon. Omalizumab responders (60.5\% of treated) were modeled as a separate scenario where nonresponders reverted back to usual care after 16 weeks of active treatment. RESULTS: The mean lifetime discounted costs and QALYs were $83,400 and 13.87 for usual care and $174,500 and 14.19 for omalizumab plus usual care resulting in $287 200/QALY (95\% interval: $219,300, $557, 900). The ICER was $172 300/QALY when comparing omalizumab to usual care in the responder scenario. One-way sensitivity analyses indicated that the results were sensitive to the difference in treatment-specific utilities for the chronic state, exacerbation-associated mortality, omalizumab price, exacerbation rates, and response definition. CONCLUSIONS: The results suggest that adding omalizumab to usual care improves QALYs at an increase in direct medical costs. The cost-effectiveness of omalizumab is similar to other chronic disease biologics. The value increases when omalizumab response is used to guide long-term treatment. This article was published in Allergy and referenced in Pharmacoeconomics: Open Access

Relevant Expert PPTs

Relevant Speaker PPTs

  • Sundeep Kumar Upadhyaya
    LONG TERM DRUG-FREE CLINICAL-REMISSION IN PATIENTS WITH RA ON cDMARDs
    PPT Version | PDF Version
  • Navinchandra G. Ashar
    Comparative study of techno-economic evaluation of the production of liquid Sulphur Di Oxide
    PDF Version
  • Vicky Stewart
    Clinical Effectiveness of Physiotherapy-led Vestibular Service in tertiary hospital
    PPT Version | PDF Version
  • Trent Jackman
    Exploratory comparison of credentialed clinical instructors’ and non-credentialed clinical instructors’ report of frequency and importance of professional behaviors in clinical education
    PPT Version | PDF Version
  • Pearl Pai
    A holistic approach to better manage the renal service and improve patient satisfaction in a new hospital and dialysis centre in China
    PPT Version | PDF Version
  • B Saranya
    Clinical presentation of ectopic pregnancy presented as PID – A case report
    PPT Version | PDF Version
  • Sribatsa Kumar Mahapatra
    Triple ABC Technique in Clinical Assessment in Breast Cancer Diagnosis
    PPT Version | PDF Version
  • Daisuke Ota
    The clinical outcome of reconstruction with tissue expander for breast cancer patients with mastectomy
    PPT Version | PDF Version
  • Brian Littlechild
    The management of violence and aggression against staff in mental health work: responding effectively through a co-production approach to issues for service users, carers, staff and agencies
    PPT Version | PDF Version
  • Suzi Demirbag
    Indications and effectiveness of the open surgery in vesicoureteral refl ux
    PPT Version | PDF Version
  • Francis Jeshira Reynoso
    The clinical phenotype of PIGN deficiency and consequences of defective GPI biogenesis
    PPT Version | PDF Version
  • Lai-Chu See
    A preliminary finding of implementing community-based hospice palliative care
    PPT Version | PDF Version
  • Nasser Nadim
    Nasser-Nadim- Clalit-Health-Organization-Services-Israel- A-different-perspective-to-white-matte
    PPT Version | PDF Version
  • Monica C Chuong
    Bioprocess Development Upstream and Downstream Technologies
    PPT Version | PDF Version
  • Yosef Yarden
    Classically, the 3’untranslated region (3’UTR) is that region in eukaryotic protein-coding genes from the translation termination codon to the polyA signal. It is transcribed as an integral part of the mRNA encoded by the gene. However, there exists another kind of RNA, which consists of the 3’UTR alone, without all other elements in mRNA such as 5’UTR and coding region. The importance of independent 3’UTR RNA (referred as I3’UTR) was prompted by results of artificially introducing such RNA species into malignant mammalian cells. Since 1991, we found that the middle part of the 3’UTR of the human nuclear factor for interleukin-6 (NF-IL6) or C/EBP gene exerted tumor suppression effect in vivo. Our subsequent studies showed that transfection of C/EBP 3’UTR led to down-regulation of several genes favorable for malignancy and to up-regulation of some genes favorable for phenotypic reversion. Also, it was shown that the sequences near the termini of the C/EBP 3’UTR were important for its tumor suppression activity. Then, the C/EBP 3’UTR was found to directly inhibit the phosphorylation activity of protein kinase CPKC in SMMC-7721, a hepatocarcinoma cell line. Recently, an AU-rich region in the C/EBP 3’UTR was found also to be responsible for its tumor suppression. Recently we have also found evidence that the independent C/EBP 3’UTR RNA is actually exists in human tissues, such as fetal liver and heart, pregnant uterus, senescent fibroblasts etc. Through 1990’s to 2000’s, world scientists found several 3’UTR RNAs that functioned as artificial independent RNAs in cancer cells and resulted in tumor suppression. Interestingly, majority of genes for these RNAs have promoter-like structures in their 3’UTR regions, although the existence of their transcribed products as independent 3’UTR RNAs is still to be confirmed. Our studies indicate that the independent 3’UTR RNA is a novel non-coding RNA species whose function should be the regulation not of the expression of their original mRNA, but of some essential life activities of the cell as a whole.
    PPT Version | PDF Version

Recommended Conferences

  • Clinical Trials
    September 11-13, 2017 San Antonio, Texas, USA

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords